



Universiteit
Leiden
The Netherlands

Interpretation of the DOME recommendations for machine learning in proteomics and metabolomics

Palmblad, M.; Bocker, S.; Degroeve, S.; Kohlbacher, O.; Kall, L.; Noble, W.S.; Wilhelm, M.

Citation

Palmblad, M., Bocker, S., Degroeve, S., Kohlbacher, O., Kall, L., Noble, W. S., & Wilhelm, M. (2022). Interpretation of the DOME recommendations for machine learning in proteomics and metabolomics. *Journal Of Proteome Research*, 21(4), 1204-1207.
doi:10.1021/acs.jproteome.1c00900

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3513394>

Note: To cite this publication please use the final published version (if applicable).

Interpretation of the DOME Recommendations for Machine Learning in Proteomics and Metabolomics

Magnus Palmblad,* Sebastian Böcker, Sven Degroeve, Oliver Kohlbacher, Lukas Käll, William Stafford Noble, and Mathias Wilhelm



Cite This: *J. Proteome Res.* 2022, 21, 1204–1207



Read Online

ACCESS |




Metrics & More



Article Recommendations

ABSTRACT: Machine learning is increasingly applied in proteomics and metabolomics to predict molecular structure, function, and physicochemical properties, including behavior in chromatography, ion mobility, and tandem mass spectrometry. These must be described in sufficient detail to apply or evaluate the performance of trained models. Here we look at and interpret the recently published and general DOME (Data, Optimization, Model, Evaluation) recommendations for conducting and reporting on machine learning in the specific context of proteomics and metabolomics.



The recently published DOME (Data, Optimization, Model, Evaluation) recommendations^{1,2} for reporting supervised machine learning (ML) research in biology aim to guide journal editors, reviewers, authors, and readers in understanding and comparing supervised ML methods and results in the biological sciences. The recommendations are designed to be general and therefore applicable to supervised ML in any biological discipline. This means that specific interpretations are needed to provide specific recommendations, examples, and guidance in fields where ML is seeing rapidly increased application. Proteomics and metabolomics are two such fields (Figure 1). Here we briefly summarize our interpretation of the DOME recommendations for the use and reporting of ML in proteomics and metabolomics with a few specific examples. Because they require different considerations, we will not cover clinical applications of ML. These are instead being addressed by other reporting standards and checklists such as MINIMAR,³ CONSORT-AI,⁴ SPIRIT-AI,⁵ and TRIPOD-ML.⁶

ML efforts in proteomics and metabolomics share many challenges and considerations because the data are derived from similar methods of chromatography, ion mobility, and mass spectrometry. Although no meta-analysis of ML method descriptions in either domain has been published, there is no reason to assume the results would be much better than those in other domains. It was recently reported for metagenomics, for example, that only 12% of published papers use a proper test set for area under the receiver operating curve (AUC) reporting.⁷

In interpreting the DOME recommendations, we follow the same structure as that in the DOME publication, with acronymized broad topics Data, Optimization, Model, and Evaluation, including general things to “be on the lookout for” (or “BOLOs” for those familiar with law enforcement jargon) and specific recommendations for the application and description of ML in proteomics or metabolomics (Table 1).

A few of the recommendations may be elaborated upon. For example, how do we know if the complexity of the modeled molecular class is sufficiently represented? For small molecules, this can be checked by comparing the coverage of compound classes according to ClassyFire¹³ or ChEBI¹⁴ with that of the intended application of the model. For peptides, a typical BOLO would be a model claimed to be applicable to all peptides trained exclusively on tryptic peptides. What constitutes a sufficient representation generally depends on both the model and its intended application.

How does one evaluate the presence of false-positives in the training data, for example, falsely identified tandem mass spectra or incorrectly assigned peaks? On one hand, such erroneously assigned spectra may confuse the model and should therefore be minimized. On the other hand, we should

Received: November 25, 2021

Published: February 4, 2022






Figure 1. Number of publications on machine learning in proteomics or metabolomics has increased rapidly in the last 5 years, as revealed by a Web of Science literature search. The results also suggest an early ML hype in these domains around 2009–2011 and a shallow but noticeable “trough of disillusionment” from 2012 to 2013. The DOME query was the same as in the original paper [$TS = \text{“machine learning” AND ALL} = (\text{“biolog*” OR “medicine” OR “genom*” OR “prote*” OR “cell*” OR “post translational” OR “metabolic” OR “clinical”})$]. The modified proteomics or metabolomics query was $TS = \text{“machine learning” AND ALL} = (\text{“biolog*” OR “medicine” OR “genom*” OR “prote*” OR “cell*” OR “post translational” OR “metabolic” OR “clinical”}) \text{ AND ALL} = (\text{“proteome” OR “proteomics” OR “metabolome” OR “metabolomics” OR “metabonome” OR “metabonomics”})$. The searches were done on 2022-01-22.

Table 1. Specific Recommendations under the Broad Topics and BOLOs as in the DOME Recommendations¹

broad topic	be on the lookout for	specific recommendations
Data	Data size and quality	Training data sufficiently represents the complexity of the modeled molecular class (e.g., tryptic peptides, lipids, all metabolites). Be clear if data used for training and testing are acquired on similar instruments (e.g., with the same mass analyzer) using similar settings (e.g., collision energy) or on a range of instruments or conditions. Beware of chimeric spectra and their possibly contaminating effects.
	Appropriate partitioning, dependence between train and test data	Training and test data should be disjoint on not only the spectrum level but also the molecular structure (e.g., peptide) level. Stereoisomers fragment highly similarly, and hence stereoisomers must not be present in the training and test sets to avoid biased statistics. Structural similarity or homology between training and test data should be kept to a minimum or should be controlled to mimic realistic test conditions. ⁸
	No access to data	Training and test data are available in a public repository ⁹ (e.g., the ProteomeXchange consortium ¹⁰). If filtering or partitioning spectra in the same data sets, provide lists of Universal Spectrum Identifiers ¹¹ defining data used to train and test the model when available. ⁴
	Other	Beware of redundancy in training or test data (e.g., multiple spectra of the same or similar molecular structures). Beware of false-positives and -negatives in training data and possible bias when selecting strict thresholds for compound identification. Beware of events affecting instrument performance over time, as those can artificially decrease or increase the apparent performance on an independent test set (e.g., instrument maintenance and calibration events).
Optimization	Overfitting, underfitting, and illegal parameter tuning	Compare with experimental variability. Is the claimed performance better than the expected experimental variability (e.g., in peak intensities or retention times)? Report any hyperparameter tuning (e.g., of deep neural network architectures).
	Imprecise parameters and protocols given	Define the optimization target (e.g., spectrum-, peptide-, or protein-level statistics). Provide the metric for comparing chromatograms or spectra (e.g., spectral angle, cosine score, or dot product) and a detailed description on how to apply it (e.g., if specific peaks for cosine score calculation were discarded, tolerances used for matching peaks, or strategies to resolve ambiguities).
Model	Unclear if black box (opaque) or interpretable (transparent) model	If the model is interpretable, describe how the trained model can be interpreted and what can be learned from it.
	No access to resulting source code and trained models	Specify which model, software, and version were used. Make documented source code publicly available.
	Execution time is impractical	Execution time for the training or application of a model should not be a bottleneck in its intended pipeline. As a rule of thumb, applying the model should not take longer than data acquisition. Execution time is even more critical in real-time applications such as continuous retention time alignment.

Table 1. continued

broad topic	be on the lookout for	specific recommendations
Evaluation	Performance measures inadequate	Motivate the use of performance measures, especially if reporting a single number. Report the Matthews correlation coefficient (MCC), not F1 scores or AUCs, for binary classifiers trained on classes of different sizes. ¹² The confusion matrix, from which other metrics can be calculated, can always be included.
	No comparisons to baselines or other methods	Compare performance with simpler baseline methods (e.g., linear regression predicting ion mobility using only mass or retention times using only amino acid composition).
	Highly variable performance	<p>Include tests measuring performance of the algorithm in a practical user situation. For example, when predicting retention time, what increase in the number of identified or quantified compounds or peptides does the prediction imply?</p> <p>Evaluate model on independent test data acquired on a different instrument in a different lab.</p> <p>Do not include peaks corresponding to the precursor ion when comparing tandem mass spectra.</p> <p>Compare models on the same data. Make sure that the metric used for comparison is the same and was applied the same (e.g., do not compare cosine scores that were calculated based on different sets of ions). If a (community-developed) benchmark data set is available, then use it. If cross-validation is employed, then report the random splits (e.g., USIs) so that others can reproduce your work. (Communities are encouraged to develop benchmarking data sets for ML).</p> <p>Explicitly state model limitations (e.g., the type and conditions of chromatography for retention time prediction or the ionization mode, fragmentation, and mass analyzer for simulating tandem mass spectra).</p>

“For training and test data sets containing millions of identified spectra, such Universal Spectrum Identifier (USI) lists will be very long. However, we expect that they would be primarily generated and read by machines, and even if they are long, USI lists take considerably less space than the mass spectra themselves. Furthermore, lists of USIs with many identifiers from the same data sets can be compressed by at least a factor of 5. More than 1 billion identifiers are already available in the ProteomeXchange repositories.

avoid overly stringent criteria that exclude compounds that intrinsically produce low-scoring compound–spectrum matches through poor or unusual fragmentation penalized in the initial scoring of the match. Ideally, practitioners should both provide a good estimate of the false-positive rate in the training data and show that the expected number of false-positives or mislabeled test data is not detrimental to the model.

As a final comment and following the recommendation to compare complex models with simple ones, we suggest that if a simple model reaches almost the same performance as a complex one, then one should always prefer the simple model, as it almost certainly has better generalizability (Occam’s razor).

Echoing suggestions by Walsh et al.¹⁵ and Jones¹⁶ and the efforts of the ELIXIR Machine Learning Focus Group¹⁷ and the AImE registry,¹⁸ we believe the domain-specific interpretation of these guidelines will be helpful to authors, reviewers, and editors in preparing and evaluating manuscripts describing work involving ML in proteomics and metabolomics in this and other journals. These recommendations should not be interpreted as absolute requirements or minimum information about an ML application in these domains but rather as a helpful first checklist. As ML is seeing rapidly expanding application in proteomics and metabolomics, best practices and reporting standards will have to be revisited in coming years. It is our hope that these recommendations will serve as a good starting point for such discussions.

AUTHOR INFORMATION

Corresponding Author

Magnus Palmblad – Center for Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; orcid.org/0000-0002-5865-8994; Email: n.m.palmblad@lumc.nl

Authors

Sebastian Böcker – Faculty of Mathematics and Computer Science, Friedrich Schiller University, 07743 Jena, Germany; orcid.org/0000-0002-9304-8091

Sven Degroev – VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium and Department of Biomolecular Medicine, Ghent University, 9052 Ghent, Belgium

Oliver Kohlbacher – Eberhard Karls Universität Tübingen, WSI/ZBIT, 72076 Tübingen, Germany; orcid.org/0000-0003-1739-4598

Lukas Käll – Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology (KTH), 171 21 Solna, Sweden; orcid.org/0000-0001-5689-9797

William Stafford Noble – Department of Genome Sciences and the Paul G. Allen School of Computer Science and Engineering, University of Washington, Seattle, Washington 98195-5065, United States; orcid.org/0000-0001-7283-4715

Mathias Wilhelm – Computational Mass Spectrometry, Technical University of Munich (TUM), 85354 Freising, Germany; orcid.org/0000-0002-9224-3258

Complete contact information is available at: <https://pubs.acs.org/10.1021/acs.jproteome.1c00900>

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

These interpretations originated in a breakout session among M.P., S.B., and M.W. and discussions with L.K. at the Dagstuhl Seminar on Computational Proteomics 21271 held July 5–9, 2021. All other authors contributed to subsequent discussions of the recommendations and the final version of the manuscript.

REFERENCES

- Walsh, I.; Fishman, D.; Garcia-Gasulla, D.; et al. DOME: recommendations for supervised machine learning validation in biology. *Nat. Methods* **2021**, *18*, 1122–1127.
- DOME-ML website. <https://dome-ml.org> (accessed 2022-02-03).
- Hernandez-Boussard, T.; Bozkurt, S.; Ioannidis, J. P. A.; Shah, N. H. MINIMAR (MINimum Information for Medical AI Reporting):

Developing reporting standards for artificial intelligence in health care. *J. Am. Med. Inform. Assoc.* **2020**, *27*, 2011–2015.

(4) Liu, X.; Cruz Rivera, S.; Moher, D.; et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. *Nat. Med.* **2020**, *26*, 1364–1374.

(5) Cruz Rivera, S.; Liu, X.; Chan, A. W.; et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. *Nat. Med.* **2020**, *26*, 1351–1363.

(6) Collins, G. S.; Reitsma, J. B.; Altman, D. G.; Moons, K. G. M. Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement. *Eur. Urol.* **2015**, *67*, 1142–1151.

(7) Quinn, T. P. Stool Studies Don't Pass the Sniff Test: A Systematic Review of Human Gut Microbiome Research Suggests Widespread Misuse of Machine Learning. *arXiv [q-bio.GN]*, July 8, 2021, 2107.03611. <https://arxiv.org/abs/2107.03611> (accessed 2022-02-03).

(8) Hobohm, U.; Scharf, M.; Schneider, R.; Sander, C. Selection of representative protein data sets. *Protein Science* vol. **1992**, *1*, 409–417.

(9) Rehfeldt, T. G.; Krawczyk, K.; Bøgebjerg, M.; Schwämmle, V.; Röttger, R. MS2AI: Automated repurposing of public peptide LC-MS data for machine learning applications. *bioRxiv* **2022**, *38*, 875.

(10) Vizcaino, J.; Deutsch, E.; Wang, R.; et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. *Nat. Biotechnol.* **2014**, *32*, 223–226.

(11) Deutsch, E. W.; Perez-Riverol, Y.; Carver, J.; et al. Universal Spectrum Identifier for mass spectra. *Nat. Methods* **2021**, *18*, 768–770.

(12) Chicco, D.; Tötsch, N.; Jurman, G. The Matthews correlation coefficient (MCC) is more reliable than balanced accuracy, bookmaker informedness, and markedness in two-class confusion matrix evaluation. *BioData Mining* **2021**, *14*, 13.

(13) Djoumbou Feunang, Y.; Eisner, R.; Knox, C.; et al. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. *J. Cheminform.* **2016**, *8*, 61.

(14) Hastings, J.; Owen, G.; Dekker, A.; et al. ChEBI in 2016: Improved services and an expanding collection of metabolites. *Nucleic Acids Res.* **2016**, *44* (D1), D1214–D1219.

(15) Walsh, I.; Pollastri, G.; Tosatto, S. C. E. Correct machine learning on protein sequences: a peer-reviewing perspective. *Brief. Bioinform.* **2016**, *17*, 831–840.

(16) Jones, D. T. Setting the standards for machine learning in biology. *Nat. Rev. Mol. Cell Biol.* **2019**, *20*, 659–660.

(17) Machine Learning Focus Group website. <https://elixir-europe.org/focus-groups/machine-learning> (accessed 2022-02-03).

(18) Matschinske, J.; et al. The AIMe registry for artificial intelligence in biomedical research. *Nat. Methods* **2021**, *18*, 1128–1131.